Top news of the week: 09.06.2020.

#Biotech #COVID19 #IPOs #NASDAQ #StockMarket #China

Startups

On Jun 4, 2020
@big4bio shared
"It just means to me that people continue to see this sector as one that's worthy of investing and that you see good returns." #Biotech #COVID19 #IPOs #StockMarket #NASDAQ https://t.co/83bSWYn4h4
Open

Biotech IPOs near last year's pace, despite COVID-19 pandemic

Biotech IPOs near last year's pace, despite COVID-19 pandemic

A successful IPO from Pliant Therapeutics is the first of five potential offerings by biotechs this week, suggesting activity is picking up following earlier coronavirus-related disruption.

On Jun 5, 2020
@adamfeuerstein shared
China’s biggest-ever Nasdaq biotech IPO comes at an awkward time https://t.co/ao1P8ET7tt Legend via @damiangarde
Open

China’s biggest-ever Nasdaq biotech IPO comes at an awkward time

China’s biggest-ever Nasdaq biotech IPO comes at an awkward time

Legend’s Wall Street success arrives as a bipartisan group of lawmakers is pushing a bill that could force it and other companies off U.S. exchanges.

On Jun 8, 2020
@BiotechWorld shared
3 months after its B round, Akouos files an IPO to the tune of $100M https://t.co/L4SWobXXTU https://t.co/qy8DMfYHRD
Open

3 months after its B round, Akouos files an IPO to the tune of $100M

3 months after its B round, Akouos files an IPO to the tune of $100M

Boston-based hearing loss gene therapy biotech Akouos is gunning for a $100 million IPO amid a near invulnerable market for public-seeking biotechs.

On Jun 5, 2020
@ForbesTech shared
Moderna hires new CFO amid race to develop coronavirus treatment https://t.co/gkaG2B74Lc https://t.co/b0poWjJfGo
Open

Moderna Hires New CFO Amid Race To Develop Coronavirus Treatment

Moderna Hires New CFO Amid Race To Develop Coronavirus Treatment

Biotech company Moderna, which is among the leaders in the race to develop a coronavirus vaccine, on Thursday named a sector veteran its new finance chief, as it gears up to launch ...

On Jun 2, 2020
@BiotechWorld shared
In conversation with Tom Lynch, president and director of Fred Hutchinson Cancer Research Center https://t.co/RAS36S6u9L https://t.co/sY3IGT7Jvx
Open

In conversation with Tom Lynch, president and director of Fred Hutchinson Cancer Research Center

In conversation with Tom Lynch, president and director of Fred Hutchinson Cancer Research Center

From chief scientific officer of Bristol Myers Squibb (back when it still had a hyphen) to running one of the biggest cancer research organizations in the world is a major career shift and ...

On Jun 3, 2020
@FierceBiotech shared
With Aduro contributing a drug and most of the money to the combined company, its shareholders will emerge with a 50% stake in Chinook. https://t.co/seFkEdAwZh
Open

Aduro, Chinook ink merger to take renal drug into phase 3

Aduro, Chinook ink merger to take renal drug into phase 3

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million to take an ex-AbbVie drug through phase 3.

On Jun 8, 2020
@big4bio shared
RT @FierceBiotech: While our listing focuses on the largest companies with the deepest pockets, it’s worth noting that Big Pharma contributed less than half of the 2019 spending tally https://t.co/rxLZXYG5fu
Open

The top 10 pharma R&D budgets in 2019

The top 10 pharma R&D budgets in 2019

In 2019, the top 10 pharmaceutical R&D spenders collectively ploughed around $82 billion into their search for new drugs, diagnostics and vaccines, around $4 billion more than the previous ...

On Jun 5, 2020
@Xconomy shared
[email protected] Raises $400M Fund to Seed Another New Set of Biotechs - by @sarahdc https://t.co/hgydmS3mWO $BMY $NVS
Open

Atlas Venture Raises $400M Fund to Seed Another New Set of Biotechs

Atlas Venture Raises $400M Fund to Seed Another New Set of Biotechs

Another venture capital firm that backs biotechs has raised a multimillion-dollar fund---money the firm, Cambridge, MA-based Atlas Venture, says it will